Date: 2015-12-11
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the San Antonio Breast Cancer Symposium (SABCS)
Company: OncoMed Pharmaceuticals (USA - CA)
Product: predictive biomarker signature for vantictumab (anti-Fzd7, OMP-18R5)
Action
mechanism: biomarker signature.
Disease: breast cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On December 11, 2015, OncoMed Pharmaceuticals presented new data related to the development of a novel predictive biomarker for vantictumab (anti-Fzd7, OMP-18R5) at the San Antonio Breast Cancer Symposium (SABCS). The presentation at SABCS detailed the identification and validation of a novel six-gene signature assay being evaluated as a predictive biomarker of response to vantictumab plus paclitaxel in the treatment of breast cancer. Vantictumab is being studied in three Phase 1b combination clinical trials, including one with paclitaxel in patients with Her2-negative breast cancer.
The six-gene Wnt pathway-related biomarker was identified by using gene expression data from breast cancer xenografts in OncoMed's patient-derived tumor bank with established in vivo response to vantictumab plus standard-of-care. The six-gene signature was tested in 18 xenograft models and effectively predicted anti-tumor responses to treatment. The biomarker was developed as a robust qPCR assay and validated with repeatability studies conducted across different days and in different labs. Prevalence of the six-gene signature is estimated to be approximately 43 percent in Her2-negative patients. In collaboration with Almac Diagnostics, the assay has been successfully developed and is being deployed in OncoMed's ongoing Phase 1b study of vantictumab in Her2-negative breast cancer.
These data were presented in a poster titled Development of a 6-gene qPCR RUO-validated assay as a predictive biomarker for response of vantictumab (OMP-18R5; anti-frizzled) in HER2- breast cancer patients (# P3-07-57) during the "Prognostic and Predictive Factors: Response Predictions — Biomarkers and Other Factors" poster session.
